Bank of America Lowers Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $462.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by equities researchers at Bank of America from $529.00 to $462.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Bank of America‘s target price would suggest a potential upside of 36.66% from the stock’s current price.

ALNY has been the topic of several other reports. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, January 15th. Royal Bank Of Canada lowered their price objective on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 20th. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 10th. Wells Fargo & Company reduced their target price on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 20th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating on the stock in a research note on Monday, October 13th. Twenty-two research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $477.13.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $338.06 on Friday. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. The firm has a market cap of $44.66 billion, a price-to-earnings ratio of 1,408.58 and a beta of 0.32. Alnylam Pharmaceuticals has a 52 week low of $205.87 and a 52 week high of $495.55. The firm’s 50-day simple moving average is $399.61 and its two-hundred day simple moving average is $424.41.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,510 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.87, for a total value of $547,933.70. Following the sale, the executive vice president owned 29,728 shares of the company’s stock, valued at $10,787,399.36. This trade represents a 4.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Yvonne Greenstreet sold 9,577 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.86, for a total value of $3,475,110.22. Following the sale, the chief executive officer owned 78,411 shares of the company’s stock, valued at approximately $28,452,215.46. This trade represents a 10.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 56,955 shares of company stock valued at $24,072,733 in the last ninety days. 1.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of ALNY. Root Financial Partners LLC bought a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth $25,000. Salomon & Ludwin LLC bought a new position in Alnylam Pharmaceuticals in the third quarter valued at $27,000. Caitong International Asset Management Co. Ltd bought a new position in Alnylam Pharmaceuticals in the third quarter valued at $29,000. Atlantic Union Bankshares Corp purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at about $30,000. Finally, Ameriflex Group Inc. bought a new stake in Alnylam Pharmaceuticals during the third quarter worth about $32,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Barclays initiated coverage with an overweight (positive) recommendation — new institutional attention and an overweight start can attract buyers and support the share price. Barclays Initiates Coverage on Alnylam
• Positive Sentiment: Bank of America lowered its price target from $529 to $462 but maintained a Buy rating (implies ~36.7% upside vs. current price), which is supportive versus a full downgrade. BofA PT cut to $462
• Positive Sentiment: HC Wainwright cut its target from $570 to $510 but kept a Buy rating (implies ~50.9% upside), another vote of confidence from a sell-side firm. HC Wainwright PT cut to $510
• Positive Sentiment: Alnylam outlined a new five‑year strategy, “Alnylam 2030,” and is projecting ~ $5.3B revenue for 2026 — strategic growth targets and a multi‑year plan can support investor confidence in long‑term upside. Alnylam projects 2026 revenue ~$5.3B
• Neutral Sentiment: Alnylam will webcast a conference call to discuss Q4 and full‑year 2025 results — standard corporate event that may move the stock depending on actual results and guidance. Webcast of Q4/FY2025 results
• Neutral Sentiment: Reported short‑interest data shows effectively zero reported short position (data appears inconsistent/placeholder); this item is unlikely to explain intraday moves. (Internal short‑interest report)
• Negative Sentiment: Morgan Stanley lowered its price target from $495 to $408 and moved to an Equal Weight rating — a visible downgrade in sentiment from a major bank which likely pressured the stock. Morgan Stanley PT cut to $408
• Negative Sentiment: Technical context: the stock is trading below both its 50‑day (~$401.57) and 200‑day (~$423.47) moving averages, which can amplify downside as trend‑following and momentum flows react.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.